Antioxidant-mediated control of degradation and drug release from surface-eroding poly(ethylene carbonate)
Source abstract
Abstract
Surface-eroding polymers are of significant interest for various applications in the field of controlled drug delivery. Poly(ethylene carbonate), as an example, offers little control over the rate of degradation and, thus, drug release, which usually conflicts with the requirements for long-acting medications. Here, we challenged an option to decelerate the degradation of poly(ethylene carbonate) in vitro and in vivo. When polymer films loaded with distinct antioxidants (vitamins) along with the model drugs leuprorelin and risperidone were incubated in superoxide radical solution and phagocyte culture, the mass loss and drug release from the delivery vehicle was a function of the type and dose of the utilized antioxidant. Once the polymer surface was "attacked" by reactive oxygen species, the antioxidants were released on demand quenching the polymer-degrading radicals. Accordingly, specific combinations of polymer and radical scavengers resulted in controlled release medications with an extended "life-time" of one month or longer, which is difficult to achieve for poly(ethylene carbonate) in the absence of antioxidants. A comparable degradation and drug release behavior was observed when antioxidant-loaded poly(ethylene carbonate) films were implanted in rats. Furthermore, linear correlations were obtained between the mass loss of the polymer films and the released fraction of drug (with slopes close to 1), a clear indication for the surface erosion of poly(ethylene carbonate) in vitro and in vivo. Overall, an addition of antioxidants to poly(ethylene carbonate)-based controlled drug delivery vehicles represents a reasonable approach to modify the performance of long-acting medications, especially when a "life time" of weeks to months needs to be achieved. STATEMENT OF SIGNIFICANCE: Surface-eroding poly(ethylene carbonate) (PEC) is of significant interest for long-acting injectable formulations. However, PEC offers only little control over the rate of degradation and, thus, drug release kinetics. We describe an option to decelerate the degradation rate of PEC in vitro and in vivo. When polymer films loaded with distinct antioxidants along with model drugs were incubated in superoxide radical solution, phagocyte culture and implanted in rats, their mass loss and drug release was a function of the type and dose of the utilized antioxidant. Accordingly, specific combinations of polymer and radical scavengers resulted in controlled release medications with an extended "life-time" of one month or longer, which is difficult to achieve for PEC in the absence of antioxidants.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: biodegradable polymer synthesis and properties · Antimicrobial agents and applications · Carbon dioxide utilization in catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (32)
Show source-provided references
1. Injectable formulations of poly(lactic acid) and its copolymers in clinical use10.1016/j.addr.2016.07.002 ↗
2. PLGA: a unique polymer for drug delivery10.4155/tde.14.91 ↗
3. Polymer degradation and drug delivery in PLGA-based drug-polymer applications: a review of experiments and theories10.1002/jbm.b.33648 ↗
4. Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms10.1002/jps.21176 ↗
5. Analysis of initial burst in PLGA microparticles10.1517/17425247.5.6.615 ↗
6. Poly(ethylene carbonate)s, part II: degradation mechanisms and parenteral delivery of bioactive agents10.1016/S0168-3659(01)00417-5 ↗
7. Enzyme-responsive surface erosion of poly(ethylene carbonate) for controlled drug release10.1016/j.ejpb.2013.04.011 ↗
8. Feasibility of macrophage mediated on-demand drug release from surface eroding poly(ethylene carbonate)10.1016/j.ijpharm.2014.02.005 ↗
9. Potential of surface-eroding poly(ethylene carbonate) for drug delivery to macrophages10.1016/j.ijpharm.2016.07.075 ↗
10. Molecular weight-dependent degradation and drug release of surface-eroding poly(ethylene carbonate)10.1016/j.ejpb.2017.02.011 ↗
11. Predicting protein instability in sustained protein delivery systems using spectral-phase interference10.1016/j.biomaterials.2011.11.037 ↗
12. Biodegradation of aliphatic and aromatic polycarbonates10.1002/mabi.200700106 ↗
13. Poly(ethylene carbonate)s, part I: syntheses and structural effects on biodegradation10.1016/S0168-3659(97)00097-7 ↗
14. Photo-cross-linked poly(ethylene carbonate) elastomers: synthesis, in vivo degradation, and determination of in vivo degradation mechanism10.1021/bm300913q ↗
15. Comparative in vitro degradation of surface-eroding poly(alkylene carbonate)s10.1016/j.polymdegradstab.2020.109186 ↗
16. Enzyme- and cell-mediated degradation of poly(ethylene carbonate) by surface erosion10.1016/j.polymdegradstab.2018.11.018 ↗
17. In vivo biocompatibility and biodegradation of poly(ethylene carbonate)10.1016/j.jconrel.2003.08.010 ↗
18. Preparation and stabilization of aqueous/ethanolic superoxide solutions10.1016/0003-2697(83)90239-7 ↗
19. A convenient route to superoxide ion in aqueous solution10.1021/ic00147a033 ↗
20. Phagocytes, oxygen reduction, and hydroxyl radical10.1093/clinids/10.6.1088 ↗
21. Oxygen-radical absorbance capacity assay for antioxidants10.1016/0891-5849(93)90027-R ↗
22. Antioxidant activity applying an improved ABTS radical cation decolorization assay10.1016/S0891-5849(98)00315-3 ↗
23. FDA – Inactive Ingredient List for Approved Drug Products,https://www.accessdata.fda.gov/scripts/cder/iig/index.Cfm (2020).
24. Enhanced anticancer efficacy of a-tocopheryl succinate by conjugation with polyethylene glycol10.1016/j.jconrel.2005.05.014 ↗
25. Cytotoxicity and genotoxicity assessment of ascorbyl palmitate (AP) food additive10.15171/apb.2018.039 ↗
26. Effect of d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) on surfactant monolayers10.1016/j.colsurfb.2011.01.021 ↗
27. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems – a review10.1016/j.ijpharm.2011.05.049 ↗
28. Development of Level A in vitro-in vivo correlations for peptide loaded PLGA microspheres10.1016/j.jconrel.2019.07.013 ↗
29. Validation of USP apparatus 4 method for microsphere in vitro release testing using Risperdal Consta10.1016/j.ijpharm.2011.08.035 ↗
30. Comparison of in vitro-in vivo release of RisperdalⓇ ConstaⓇ microspheres10.1016/j.ijpharm.2012.05.006 ↗
31. Validation of a cage implant system for assessing in vivo performance of long-acting release microspheres10.1016/j.biomaterials.2016.07.041 ↗
32. Characterizing the release mechanism of donepezil-loaded PLGA microspheres in vitro and in vivo10.1016/j.jddst.2019.03.029 ↗